Table 2.
Clinical characteristics of the ASCP patients from SEER in the development and internal validation cohorts.
| Characteristics | Development cohorts (N = 165) | Internal validation cohorts (N = 68) |
|---|---|---|
| Diagnosed age | 67 (59-73) | 70 (63-75) |
| Race | ||
| Black | 16 | 6 |
| White | 139 | 54 |
| Others | 10 | 8 |
| Sex | ||
| Female | 91 | 27 |
| Male | 74 | 41 |
| Tumor location | ||
| Body or tail | 67 | 24 |
| Head | 79 | 37 |
| Others | 19 | 7 |
| Grades | ||
| I+II | 39 | 15 |
| III+IV | 102 | 47 |
| Unknown | 24 | 6 |
| AJCC stages (8th) | ||
| I | 37 | 18 |
| II | 95 | 30 |
| III | 33 | 20 |
| T Stage (8th) | ||
| T1 | 8 | 3 |
| T2 | 76 | 33 |
| T3 | 71 | 27 |
| T4 | 10 | 5 |
| N Stage (8th) | ||
| N0 | 69 | 26 |
| N1 | 72 | 25 |
| N2 | 24 | 17 |
| Radiotherapy | ||
| No | 119 | 58 |
| Yes | 46 | 10 |
| Chemotherapy | ||
| No | 59 | 25 |
| Yes | 106 | 43 |
| Number of examined lymph nodes | 14 (9-22) | 16 (11-22.75) |
| Tumor size | 40 (30-55) | 40 (30-50) |
| LNR | 0.070 (0-0.185) | 0.007(0-0.208) |